leisure time -WSS

leisure time

author：comprehensive 2025-09-28 16:34:48 - browse：2742

Warning sign illustration made of 0s and 1s. -- first opinion coverage from sTAT — Adobe

Big businesses poised to profit from the advance of artificial intelligence in health care are pushing back against newly proposed federal rules meant to increase oversight and fairness of AI tools used to help make decisions about patient care.

The opposition, which includes Google and Amazon as well as large health care providers, insurers, and medical software vendors, is focused on an attempt to put tighter guardrails around the use of AI by the Office of the National Coordinator for Health Information Technology.

The agency wants to require developers of electronic health records and other health software to provide users with details about the training and testing of predictive models that draw data from their systems, or are hosted within them. It also wants developers to assess and publicly disclose potential risks and create a way for clinicians and other users to report problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Why don't Americans have at

WSS

North Korean leader's powerful sister says warplanes repelled US spy plane

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

AMAs digital advisors table RPM coding reform proposal, again

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Sen. Bill Cassidy on how to lower drug prices

Study gives hint on South Asians’ higher risk of cardiovascular disease

explore

leisure time

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Trump demands the U.S. pay no more for drugs than other countries … again

Too many hospitalized Covid

How one medical school became remarkably diverse

Websites selling Wegovy, Zepbound ingredients targeted by FDA

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

ACIP vaccine advisory panel sees its vacancies filled

Psychedelics group wrestles with new pharma identity

Trump seeks lengthy delay of classified docs trial, citing upcoming election

explore

Artificial intelligence use in health care faces greater scrutiny in 2024

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Eli Lilly reports tirzepatide MASH success during Q4 earnings

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Long Covid research funding gets a major boost from NIH

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Wikipedia

explore

focus

focus